Role of angiotensin receptor blockers in the prevention and management of ischaemic stroke

European Journal of Neurology

Volumn 14, Issue 11, 2007, Pages 1201-1209

  Mathur, G ^a   Cleland, J G F ^a   Rodrigues, E ^b   Davis, G K ^b  

^a UNIVERSITY OF HULL   (United Kingdom)

^b UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

Angiotensin receptor blockers; Stroke

Indexed keywords

AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIHYDROPYRIDINE; ENALAPRIL; EPROSARTAN; INDAPAMIDE; IRBESARTAN; LOSARTAN; NITRENDIPINE; OLMESARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; VALSARTAN;

BRAIN ISCHEMIA; BRAIN PROTECTION; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; HYPERTENSION; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; REVIEW; STROKE;

ANTIHYPERTENSIVE AGENTS; BRAIN ISCHEMIA; HUMANS; RECEPTORS, ANGIOTENSIN; STROKE;

EID: 35448936905     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2007.01950.x     Document Type: Review

References (72)

1. MacMahon S, Peto R, Collins R, et al. Blood pressure, stroke, and coronary heart disease:part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. The Lancet 1990 335:765 774.
2. MacMahon S, Rodgers A. Blood pressure, antihypertensive treatment and stroke risk. Journal of Hypertension 1994 12 (Suppl. 10 S5 S14.
3. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). The Journal of the American Medical Association 1991 265:3255 3264.
4. Leenen FH. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome. Canadian Journal of Cardiology 2004 20 (Suppl. B 77B 82B.
5. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. British medical journal (Clinical research ed.) 1985 291:97 104.
6. PATS Collaborating Group. Post-stroke antihypertensive treatment study. A preliminary result. Chinese Medical Journal 1995 108:710 717.
7. MRC Working Party. Medical research council trial of treatment of hypertension in older adults: principal results. British Medical Journal 1992 304:405 412.
8. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). The Journal of the American Medical Association 2000 283:1967 1975.
9. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). The Journal of the American Medical Association 2002 288:2981 2997.
10. Wright JT Jr., Dunn JK, Cutler JA, et al. Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril. The Journal of the American Medical Association 2005 293:1595 1608.
11. Brewster LL, Kleijnen J, van Montfrans GA. Effect of antihypertensive drugs on mortality, morbidity and blood pressure in blacks. Cochrane Database of Systematic Reviews 2005 CD005183.
12. Goldenberg I, Moss AJ, Ryan D, McNitt S, Eberly SW, Zareba W. Polymorphism in the angiotensinogen gene, hypertension, and ethnic differences in the risk of recurrent coronary events. Hypertension 2006 48:693 699.
13. Wang X, Zhu H, Dong Y, Treiber FA, Snieder H. Effects of angiotensinogen and angiotensin II type I receptor genes on blood pressure and left ventricular mass trajectories in multiethnic youth. Twin Research and Human Genetics 2006 9:393 402.
14. Woodiwiss AJ, Nkeh B, Samani NJ, et al. Functional variants of the angiotensinogen gene determine antihypertensive responses to angiotensin-converting enzyme inhibitors in subjects of African origin. Journal of Hypertension 2006 24:1057 1064.
15. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood pressure lowering treatment trialists' collaboration. Lancet 2000 356:1955 1964.
16. Angeli F, Verdecchia P, Reboldi GP, et al. Calcium channel blockade to prevent stroke in hypertension: a meta-analysis of 13 studies with 103,793 subjects. American Journal of Hypertension 2004 17:817 822.
17. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian cardiac outcomes trial-blood pressure lowering arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 366:895 906.
18. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005 366:1545 1553.
19. Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke: double blind randomised trial. British Medical Journal 2002 324:699 702.
20. Perry HM Jr., Davis BR, Price TR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the systolic hypertension in the elderly program (SHEP). The Journal of the American Medical Association 2000 284:465 471.
21. Mooe T, Olofsson BO, Stegmayr B, Eriksson P. Ischemic stroke. Impact of a recent myocardial infarction. Stroke 1999 30:997 1001.
22. Perindopril Protection Against Recurrent Stroke Study (PROGRESS) Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 358:1033 1041.
23. Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005 46:386 392.
24. Fournier A, Messerli FH, Achard JM, Fernandez L. Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. Journal of the American College of Cardiology 2004 43:1343 1347.
25. Ovbiagele B, Kidwell CS, Starkman S, et al. Angiotensin 2 type 2 receptor activity and ischemic stroke severity. Neurology 2005 65:851 854.
26. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 359:995 1003.
27. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004 363:2022 2031.
28. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. New England Journal of Medicine 2001 345:870 878.
29. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002 106:672 678.
30. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. New England Journal of Medicine 2001 345:851 860.
31. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine 2001 345:861 869.
32. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE). Lancet 1997 349:747 752.
33. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the losartan heart failure survival study ELITE II. Lancet 2000 355:1582 1587.
34. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. New England Journal of Medicine 2001 345:1667 1675.
35. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-overall programme. Lancet 2003 362:759 766.
36. Solomon SD, Wang D, Finn P, et al. Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program. Circulation 2004 110:2180 2183.
37. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999 100:1056 1064.
38. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New England Journal of Medicine 2003 349:1893 1906.
39. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. The Lancet 2002 360:752 760.
40. Lithell H, Hansson L, Skoog I, et al. The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial. Journal of Hypertension 2003 21:875 886.
41. Lithell H, Hansson L, Skoog I, et al. The study on cognition and prognosis in the elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. Journal of Hypertension 2004 22:1605 1612.
42. Kizer JR, Dahlof B, Kjeldsen SE, et al. Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the losartan intervention for endpoint reduction in hypertension study. Hypertension 2005 45:46 52.
43. Papademetriou V, Farsang C, Elmfeldt D, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the study on cognition and prognosis in the elderly (SCOPE). Journal of the American College of Cardiology 2004 44:1175 1180.
44. Kjeldsen SE, Lyle PA, Kizer JR, et al. The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study. Journal of Clinical Hypertension (Greenwich) 2005 7:152 158.
45. Britton M, Carlsson A, de Faire U. Blood pressure course in patients with acute stroke and matched controls. Stroke 1986 17:861 864.
46. Ahmed N, Wahlgren G. High initial blood pressure after acute stroke is associated with poor functional outcome. Journal of Internal Medicine 2001 249:467 473.
47. Rodriguez-Garcia JL, Botia E, de La SA, Villanueva MA, Gonzalez-Spinola J. Significance of elevated blood pressure and its management on the short-term outcome of patients with acute ischemic stroke. American Journal of Hypertension 2005 18:379 384.
48. Carlberg B, Asplund K, Hagg E. The prognostic value of admission blood pressure in patients with acute stroke. Stroke 1993 24:1372 1375.
49. Vemmos KN, Tsivgoulis G, Spengos K, et al. U-shaped relationship between mortality and admission blood pressure in patients with acute stroke. Journal of Internal Medicine 2004 255:257 265.
50. Willmot M, Leonardi-Bee J, Bath PM. High blood pressure in acute stroke and subsequent outcome: a systematic review. Hypertension 2004 43:18 24.
51. Castillo J, Leira R, Garcia MM, Serena J, Blanco M, Davalos A. Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke 2004 35:520 526.
52. Adams H, Adams R, Del Zoppo G, Goldstein LB. Guidelines for the Early Management of Patients With Ischemic Stroke: 2005 Guidelines Update A Scientific Statement From the Stroke Council of the American Heart Association/American Stroke Association. Stroke 2005 36:916 923.
53. Schrader J, Luders S, Kulschewski A, et al. The ACCESS study: evaluation of acute Candesartan Cilexetil therapy in stroke survivors. Stroke 2003 34:1699 1703.
54. Kernan WN. Re: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003 34:e237 e238.
55. Michel P, Bogousslavsky J. ACCESS study: blood pressure effect Stroke 2003 34:e237 e238.
56. Schrader J, Luders S, Kulschewski A, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005 36:1218 1226.
57. Trenkwalder P, Elmfeldt D, Hofman A, et al. The study on cognition and prognosis in the elderly (SCOPE) - major CV events and stroke in subgroups of patients. Blood Pressure 2005 14:31 37.
58. Boulanger JM, Hill MD. Morbidity and mortality after stroke - eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2006 37:335 336.
59. Fournier A, Choukroun G, Modeliar SS, et al. Does the MOSES trial establish superiority of AT1-receptor blockers over dihydropyridine/calcium antagonists in secondary stroke prevention Stroke 2006 37:336 337.
60. Owen A. MOSES: superiority or noninferiority Stroke 2006 37:337.
61. Struck J, Muck P, Trubger D, et al. Effects of selective angiotensin II receptor blockade on sympathetic nerve activity in primary hypertensive subjects. Journal of Hypertension 2002 20:1143 1149.
62. Groth W, Blume A, Gohlke P, Unger T, Culman J. Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats. Journal of Hypertension 2003 21:2175 2182.
63. Engelhorn T, Goerike S, Doerfler A, et al. The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. Journal of Cerebral Blood Flow and Metabolism 2004 24:467 474.
64. Fernandez LA, Caride VJ, Stromberg C, Naveri L, Wicke JD. Angiotensin AT2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation. Journal of Cardiovascular Pharmacology 1994 24:937 940.
65. Li J, Culman J, Hortnagl H, et al. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB Journal 2005 19:617 619.
66. Gendron L, Payet MD, Gallo-Payet N. The angiotensin type 2 receptor of angiotensin II and neuronal differentiation: from observations to mechanisms. Journal of Molecular Endocrinology 2003 31:359 372.
67. Aldred GP, Chai SY, Song K, Zhuo J, MacGregor DP, Mendelsohn FA. Distribution of angiotensin II receptor subtypes in the rabbit brain. Regulatory Peptides 1993 44:119 130.
68. Ito T, Yamakawa H, Bregonzio C, Terron JA, Falcon-Neri A, Saavedra JM. Protection against ischemia and improvement of cerebral blood flow in genetically hypertensive rats by chronic pretreatment with an angiotensin II AT1 antagonist. Stroke 2002 33:2297 2303.
69. Walther T, Olah L, Harms C, et al. Ischemic injury in experimental stroke depends on angiotensin II. FASEB Journal 2002 16:169 176.
70. Iwai M, Liu HW, Chen R, et al. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 2004 110:843 848.
71. Munzenmaier DH, Greene AS. Chronic angiotensin II AT1 receptor blockade increases cerebral cortical microvessel density. American Journal of Physiology. Heart and Circulatory Physiology 2006 290:H512 H516.
72. Forder JP, Munzenmaier DH, Greene AS. Angiogenic protection from focal ischemia with angiotensin II type 1 receptor blockade in the rat. American Journal of Physiology. Heart and Circulatory Physiology 2005 288:H1989 H1996.